MedTrace Logo

Invasive Disease Caused by Group A Streptococcus (GAS) (DICAR)

NCT03507101 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2023-04-14

No results posted yet for this study

Summary

The goal of this study is to gain important knowledge on the pathogenesis and prognostic factors in severe invasive group A streptococcal (GAS) infections, as well as the effects of individual characteristics of both the pathogen and the patient on disease severity. The aim is to recruit a minimum of 60 patients from Tampere and Turku University Hospitals in 2-3 years to gather a suitably wide spectrum of manifestations of the disease, and gather genetic, transcriptomic and diagnostic data on both the patients and pathogens in an effort to further our understanding of the pathogenesis of severe invasive GAS disease.

Conditions

  • Invasive Group A Beta-Haemolytic Streptococcal Disease

Interventions

OTHER

No intervention

No particular intervention or exposure is of particular interest

Sponsors & Collaborators

  • Turku University Hospital

    collaborator OTHER_GOV

  • University of Turku

    collaborator OTHER

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Jaana Syrjänen, PhD · Tampere University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2021-07-01
Completion
2024-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03507101 on ClinicalTrials.gov